This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Paul Thacker | |
|---|---|
| Name | Paul Thacker |
| Occupation | Investigative journalist |
| Notable works | Reporting on pharmaceutical and FDA practices |
Paul Thacker is an investigative journalist known for reporting on conflicts of interest in biomedical research, pharmaceuticals, and regulatory affairs involving the Food and Drug Administration and academic institutions. He has written for outlets that focus on public health, science policy, and medical ethics, and has been cited by policymakers, academics, and media organizations. Thacker's work has prompted debates involving universities, journals, corporations, and federal agencies.
Thacker was born in the United States and raised in a milieu connected to American media and civic institutions such as Congress, NIH, and regional press outlets. He studied subjects that intersect with reporting on medical research, drawing on curricula found at institutions like Harvard University, Johns Hopkins University, Columbia University, and Georgetown University. During his formative years he engaged with student publications and nonprofit organizations related to public policy and ethics similar to groups at Yale University and University of Pennsylvania. His training included familiarity with investigative techniques practiced by reporters at The New York Times, The Washington Post, ProPublica, and Reuters.
Thacker's career spans positions at nonprofit watchdog organizations, investigative outlets, and freelance journalism contributing to publications such as The New York Times, The Guardian, BMJ, Stat News, and specialty science publications. He has been affiliated with nonprofit investigative groups resembling Center for Public Integrity, Project on Government Oversight, and advocacy organizations focused on medical research transparency. Thacker has collaborated with legal teams, academics at institutions such as Stanford University and University of California, San Francisco, and journalists from outlets like The Washington Post, Los Angeles Times, and Bloomberg News on cross‑institutional investigations. He frequently uses public records laws modeled on the Freedom of Information Act and works with librarians and data specialists who use resources at the National Library of Medicine and archives linked to Congressional Research Service reports.
Thacker's reporting has targeted pharmaceutical companies including Pfizer, Merck & Co., Johnson & Johnson, and GlaxoSmithKline, and examined relationships between those companies and academic journals such as The Lancet, New England Journal of Medicine, JAMA, and BMJ. He has published pieces on conflicts of interest involving investigators at universities like Harvard Medical School, Yale School of Medicine, University of California, San Francisco, and Vanderbilt University Medical Center. His investigations have explored regulatory conduct at the Food and Drug Administration and funding patterns tied to agencies like the National Institutes of Health and foundations reminiscent of the Gates Foundation. Thacker has reported on pharmaceutical advertising practices aligned with standards from FTC and interactions between lobbyists registered with the United States Senate and United States House of Representatives. His work has been cited in policy discussions at Centers for Disease Control and Prevention meetings and in academic critiques published through venues such as PLOS Medicine and Nature Medicine.
Thacker's methods and conclusions have drawn criticism from corporate spokespeople at firms like Pfizer and academic leaders at institutions including Duke University and Columbia University. Defenders of pharmaceutical and academic collaborations have invoked standards from entities such as the International Committee of Medical Journal Editors and cited legal precedents from federal courts. Some journalists at The New York Times and The Wall Street Journal have debated his framing, while ethicists associated with Johns Hopkins Berman Institute of Bioethics and scholars publishing in The Lancet have questioned aspects of attribution or context. At times media organizations have published corrections or editorial discussions comparable to those at The Guardian and Stat News when disputes arose over sourcing or interpretation. Advocacy groups and transparency proponents, including organizations similar to Transparency International and OpenSecrets, have supported Thacker's emphasis on disclosure.
Thacker has received recognition from journalism and public interest organizations akin to awards from the Society of Professional Journalists, investigative prizes similar to those conferred by Investigative Reporters and Editors, and commendations from public‑health advocacy groups. His reporting has been cited in academic papers published in JAMA, BMJ, and PLOS Medicine and discussed at conferences hosted by entities like American Public Health Association and Health Affairs symposia. Think tanks and policy centers such as Kaiser Family Foundation and university centers focused on bioethics have invited him to speak about transparency in research and regulation.
Thacker resides in the United States and maintains professional connections with investigative journalists, academics at institutions like Harvard School of Public Health and Yale School of Medicine, and nonprofit transparency organizations. He participates in forums and panels alongside editors from The New York Times, researchers from National Institutes of Health, and ethicists from Georgetown University. Outside journalism he engages with issues related to public accountability and contributes to discussions involving regulatory affairs at meetings of groups similar to the Food and Drug Law Institute.
Category:American journalists Category:Investigative journalists